Search results
Showing 16 to 24 of 24 results for dupilumab
In development Reference number: GID-TA11615 Expected publication date: TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Awaiting development Reference number: GID-TA11383 Expected publication date: TBC
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC